Abstract
Background and Hypothesis Psychosis-related environmental risks are common in autism, with identified genetic connections to psychosis. Therefore, we hypothesized these risks may moderate the relationship between autistic traits (ATs) and psychotic experiences (PEs).
Study Design First-wave data from 792 twins and siblings in the TwinssCan Project were analysed (n=792). PEs and ATs were assessed using the Community Assessment of Psychic Experiences and the Autism-Spectrum Quotient. Polygenic risk scores for schizophrenia and psychosis-associated environmental factors (childhood trauma (CT), bullying, negative life events, obstetric complications, cannabis use, winter birth, and hearing impairment) were tested for independent and interactive effects with ATs using separate multilevel linear regression models.
Study Results ATs, all five CT subtypes, bullying, and negative life events were significantly associated with PEs (all P < 0.004). Emotional abuse (B: 0.08, 95% CI:0.05 to 0.11, P < 0.001), physical abuse (B: 0.11, 95% CI: 0.05 to 0.18, P = 0.001), sexual abuse (B: 0.09, 95% CI: 0.03 to 0.15, P = 0.002), and physical neglect (B: 0.06, 95% CI: 0.03 to 0.10, P = 0.001) significantly amplified the positive relationship between ATs and PEs, whereas emotional neglect (B: 0.04, 95% CI: 0.01 to 0.07, P = 0.007) and negative life events (B: 0.007, 95% CI: 0.0005 to 0.014, P = 0.04) only showed a trend of interactions. No significant main or interacting effects of genetic and other risk factors were found.
Conclusions These findings imply that CT might be a potential preventive target for psychosis expression in people with high ATs.
Competing Interest Statement
Marco Colizzi has been a consultant/advisor to GW Pharma Limited, GW Pharma Italy SRL and F. Hoffmann-La Roche Limited, outside of this work. The other authors have declared no competing interest.
Funding Statement
The East Flanders Prospective Twin Survey (EFPTS) received support from the Association for Scientific Research in Multiple Births (Belgium) and that the TwinssCan project is funded by the European Community Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). This work was further supported by the Scientific and Technological Research Council of Turkiye (TUBITAK), 2219 International Postdoctoral Research Fellowship under grant number 1059B192302449 to M.K.D., by Ophelia research project, ZonMw under grant number 36340001 to J.V.O. and S.G., the Netherlands Scientific Organisation Vidi award under grant number 91718336 to B.P.F.R., the European Union Horizon Europe program, YOUTH-GEMs Project under grant number 01057182 to J.V.O., L.K.P., B.D.L., B.P.F.R., S.G. and A.A.M. and by #NEXTGENERATIONEU (NGEU) from the Ministry of University and Research (MIUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006) A Multiscale integrated approach to the study of the nervous system in health and disease to L.F.P. (DN. 1553 11.10.2022). T.P. received research training funding from the Faculty of Medicine Ramathibodi Hospital, Mahidol University. L.K.P. was a recipient of the Kootstra Talent Fellowship of Maastricht University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee research of KU Leuven (Commissie Medische Ethiek van de Universitaire Ziekenhuizen KU Leuven, Nr. B32220107766) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
